Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Hepatitis

Free Subscription Articles published in J Infect Dis Retrieve available abstracts of 75 articles: HTML format

Single Articles

October 2023
1. IVANOVA REIPOLD E, Shilton S, Donolato M, Fernandez Suarez M, et al
   Molecular point of care testing for hepatitis C: available technologies, pipeline and promising future directions.
   J Infect Dis. 2023 Oct 28:jiad463. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. FELD JJ
   What is needed to move toward single-step diagnosis of current HCV infection?
   J Infect Dis. 2023 Oct 13:jiad453. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. FALADE-NWULIA O, Lesko CR, Fojo AT, Keruly JC, et al
   Hepatitis C treatment in people living with HIV: Potential to eliminate disease and disparity.
   J Infect Dis. 2023 Oct 5:jiad433. doi: 10.1093.
   PubMed     Abstract available
   
   
   September 2023
4. FRICKER GP, Ghany MG, Mera J, Pinsky BA, et al
   Tools Needed to Support Same-day Diagnosis and Treatment of Current Hepatitis C Infection.
   J Infect Dis. 2023 Sep 22:jiad177. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. CARTWRIGHT EJ, Patel PR
   Opportunities for enhanced prevention and control of hepatitis C through improved screening and testing efforts.
   J Infect Dis. 2023 Sep 22:jiad199. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. JOHNSON LN, Gaynor AM, Wroblewski K, Buss SN, et al
   Maximizing Reflexive HCV RNA Testing of HCV Antibody-Reactive Samples Within United States Public Health Laboratories.
   J Infect Dis. 2023 Sep 22:jiad191. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. TERRAULT N
   Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis.
   J Infect Dis. 2023 Sep 22:jiad299. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. PAGE K, Feinberg J
   What Hepatitis C (HCV) diagnostic tools are needed to advance diagnosis of current HCV infection in outreach settings and in a non-clinical setting?
   J Infect Dis. 2023 Sep 22:jiad269. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. HANDANAGIC S, Shadaker S, Drobeniuc J, Tsereteli M, et al
   Lessons learned from global hepatitis C elimination programs.
   J Infect Dis. 2023 Sep 22:jiad198. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. LOU S, Wang J, Chen J, Xie H, et al
    The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon alpha Therapy.
    J Infect Dis. 2023;228:694-703.
    PubMed     Abstract available
    
    
    
11. CHIEN RN, Lu SN, Hui-Min Wu G, Yang WW, et al
    Policy and Strategy for Hepatitis C Virus Elimination at the National Level: Experience in Taiwan.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
12. KONDILI LA, Craxi L, Nava F, Babudieri S, et al
    From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
13. AARON A, Zhong H, Hiebert L, Zhuo Y, et al
    Hepatitis C Elimination in Moldova Is Feasible and Cost-Saving: A Modeling Study.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
14. QURESHI H, Mahmood H, Sabry A, Hermez J, et al
    Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
15. WASITTHANKASEM R, Wanlapakorn N, Pimsing N, Posuwan N, et al
    Simplified Test-to-Treat Strategy for Hepatitis C in Thailand: The Phetchabun Model.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
16. NJUGUNA HN, Hiebert L, Harris A, Morgan RL, et al
    An Assessment of National Strategic Action Plans for Viral Hepatitis Elimination, 2016-2021.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
17. PRZYBYSZEWSKI EM, Chung RT
    Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
18. HUANG CF, Chen GJ, Hung CC, Yu ML, et al
    HCV Microelimination for High-risk Special Populations.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
19. ADDA D, James C, Peck R, Ali M, et al
    The Role of Nonprofit and Nongovernmental Organizations and People With Viral Hepatitis on the Path Toward Hepatitis C Virus Elimination.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
20. YU ML, Ward JW
    Sharing Lessons Learned to Build Effective Hepatitis Elimination Programs.
    J Infect Dis. 2023;228.
    PubMed    
    
    
    
21. UMUTESI J, Yu ML, Lesi O, Ward JW, et al
    Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
22. SPAULDING AC, Kennedy SS, Osei J, Sidibeh E, et al
    Estimates of Hepatitis C Seroprevalence and Viremia in State Prison Populations in the United States.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
23. 
    Correction to: Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated With Nucleos(t)ide Analogues.
    J Infect Dis. 2023 Sep 7:jiad376. doi: 10.1093.
    PubMed    
    
    
    July 2023
24. POWELL JG, Goble SR, Debes JD
    Re-vaccination For Hepatitis B in Previous Non-Responders Following Hepatitis C Eradication.
    J Infect Dis. 2023 Jul 31:jiad301. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. FIERER DS, Schinkel J
    Redefining the Paradigm: The Role of Sexual Networks and Sexualized Drug Use in the Transmission of HCV Among Men Who Have Sex with Men.
    J Infect Dis. 2023 Jul 24:jiad265. doi: 10.1093.
    PubMed    
    
    
    
26. JUNG CY, Jung HY, Kim HW, Ryu GW, et al
    Fibrotic burden in patients with hepatitis B virus-related cirrhosis is independently associated with poorer kidney outcomes.
    J Infect Dis. 2023 Jul 20:jiad273. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2023
27. ARTENIE A, Stone J, Facente SN, Fraser H, et al
    Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.
    J Infect Dis. 2023 Jun 24:jiad169. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2023
28. TANG X, Yang L, Zhang P, Wang C, et al
    Occult hepatitis B virus infection is associated with Chinese patients' liver fibrosis.
    J Infect Dis. 2023 May 12:jiad140. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. THIO CL, Taddese M, Saad Y, Zambo K, et al
    HBeAg-negative single hepatocyte analysis shows transcriptional silencing and slow decay of infected cells with treatment.
    J Infect Dis. 2023 May 2:jiad124. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2023
30. WINCHESTER NE, Shrestha NK, Kim P, Tereshchenko LG, et al
    Protection Conferred by Delta and BA.1/BA.2 Infection Against BA.4/BA.5 Infection and Hospitalization: A Retrospective Cohort Study.
    J Infect Dis. 2023;227:800-805.
    PubMed     Abstract available
    
    
    
31. GAMKRELIDZE A, Shadaker S, Tsereteli M, Alkhazashvili M, et al
    Nationwide hepatitis C serosurvey and progress towards HCV elimination in the country of Georgia, 2021.
    J Infect Dis. 2023 Mar 18:jiad064. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. SUEHIRO Y, Tsuge M, Kurihara M, Uchida T, et al
    Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL.
    J Infect Dis. 2023;227:686-695.
    PubMed     Abstract available
    
    
    February 2023
33. SACHITHANANDHAM J, Balagopal A, Leep-Lazar J, Quinn J, et al
    Second-phase hepatitis C plasma viral kinetics directly reflects reduced intrahepatic burden of HCV.
    J Infect Dis. 2023 Feb 1:jiad025. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2023
34. THOMPSON P, Parr JB, Boisson A, Razavi-Shearer D, et al
    Now is the Time to Scale Up Birth Dose Hepatitis Vaccine in Low and Middle-Income Countries.
    J Infect Dis. 2023 Jan 31:jiad026. doi: 10.1093.
    PubMed    
    
    
    December 2022
35. YU T, Zhang M, Zhang H, Zheng J, et al
    Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated with Nucleos(t)ide Analogues.
    J Infect Dis. 2022 Dec 22:jiac493. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2022
36. LIND ML, Copin R, McCarthy S, Coppi A, et al
    Use of whole genome sequencing to estimate the contribution of immune evasion and waning immunity on decreasing COVID-19 vaccine effectiveness.
    J Infect Dis. 2022 Nov 21:jiac453. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2022
37. MILLER-ARCHIE SA, Walters SC, Bocour A, Moore MS, et al
    The Impact of Supportive Housing on Liver-Related Outcomes Among Persons With Hepatitis C Virus Infection.
    J Infect Dis. 2022;226.
    PubMed     Abstract available
    
    
    September 2022
38. HALL SA, Burns GS, Mooney BJ, Millen R, et al
    Hepatitis B Virus Flares following Nucleot(s)ide Analogue Cessation Are Associated with Activation of TLR Signalling Pathways.
    J Infect Dis. 2022 Sep 15. pii: 6701634. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2022
39. VETTER BN, Reipold EI, Ongarello S, Audu R, et al
    Sensitivity and Specificity of Rapid Diagnostic Tests for Hepatitis C Virus With or Without HIV Coinfection: A Multicentre Laboratory Evaluation Study.
    J Infect Dis. 2022;226:420-430.
    PubMed     Abstract available
    
    
    
40. OGAWA E, Nomura H, Nakamuta M, Furusyo N, et al
    Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
    J Infect Dis. 2022;226:431-440.
    PubMed     Abstract available
    
    
    
41. KITABAYASHI J, Shirasaki T, Shimakami T, Nishiyama T, et al
    Upregulation of the Long Noncoding RNA HULC by Hepatitis C Virus and Its Regulation of Viral Replication.
    J Infect Dis. 2022;226:407-419.
    PubMed     Abstract available
    
    
    
42. GARDNER AR, Ma Y, Bacchetti P, Price JC, et al
    Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment.
    J Infect Dis. 2022 Aug 11. pii: 6650396. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2022
43. PEREZ-GARCIA F, Vazquez-Moron S, Burgueno-Garcia I, Jose Munoz-Gomez M, et al
    Hepatitis E virus seroprevalence is associated with neurodegenerative disorders in older people with dementia: a case-control study.
    J Infect Dis. 2022 Jun 27. pii: 6618639. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. SONNEVELD MJ, Hansen BE, Brouwer WP, Chan HL, et al
    Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study.
    J Infect Dis. 2022;225:1967-1973.
    PubMed     Abstract available
    
    
    May 2022
45. OSTER G, Bornheimer R, Ottino K
    Letter to the Editor in Response to Hall EW, Weng MK, Harris AM, et al. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults.
    J Infect Dis. 2022 May 26. pii: 6593317. doi: 10.1093.
    PubMed    
    
    
    
46. BRAKENHOFF SM, de Knegt RJ, Oliveira J, van der Eijk AA, et al
    Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients.
    J Infect Dis. 2022 May 23. pii: 6590452. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. MOHAREB AM, Liu AF, Kim AY, Coffie PA, et al
    Clearance of hepatitis B "e" antigen in untreated chronic HBV infection: a systematic review and meta-analysis.
    J Infect Dis. 2022 May 2. pii: 6576758. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2022
48. MONTANARI NR, Conceicao-Neto N, Van Den Wyngaert I, Van Oord GW, et al
    Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients.
    J Infect Dis. 2022;225:1471-1476.
    PubMed     Abstract available
    
    
    March 2022
49. RICO MONTANARI N, Ramirez R, Van Buuren N, van den Bosch TPP, et al
    Transcriptomic Analysis of Livers of Inactive Carriers of Hepatitis B Virus With Distinct Expression of Hepatitis B Surface Antigen.
    J Infect Dis. 2022;225:1081-1090.
    PubMed     Abstract available
    
    
    
50. HALL EW, Weng MK, Harris AM, Schillie S, et al
    Assessing the cost-utility of universal hepatitis B vaccination among adults.
    J Infect Dis. 2022 Mar 9. pii: 6545195. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2022
51. CATLETT B, Hajarizadeh B, Cunningham E, Wolfson-Stofko B, et al
    Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of HCV RNA: a systematic review.
    J Infect Dis. 2022 Feb 12. pii: 6527696. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2022
52. SPRADLING PR, Xing J, Zhong Y, Rupp LB, et al
    Incidence of malignancies among patients with chronic hepatitis B in US health care organizations, 2006-2018.
    J Infect Dis. 2022 Jan 17. pii: 6510085. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. KHALFI P, Suspene R, Caval V, Thiers V, et al
    APOBEC3C S188I polymorphism enhances context specific editing of Hepatitis B virus genome.
    J Infect Dis. 2022 Jan 12. pii: 6504007. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2021
54. LIU S, Deng R, Zhou B, Liang X, et al
    Association of serum hepatitis B virus RNA with hepatocellular carcinoma risk in chronic hepatitis B patients under nucleos(t)ide analogues therapy.
    J Infect Dis. 2021 Dec 21. pii: 6472568. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. CHIEN-HUNG C, Peng CY, Kuo YH, Hu TH, et al
    Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in HBeAg-positive patients.
    J Infect Dis. 2021 Dec 11. pii: 6459556. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. COSTAFREDA MI, Sauleda S, Rico A, Piron M, et al
    Detection of non-enveloped hepatitis E virus in plasma of infected blood donors.
    J Infect Dis. 2021 Dec 4. pii: 6449510. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2021
57. STOCKDALE AJ, Meiring JE, Shawa IT, Thindwa D, et al
    Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi.
    J Infect Dis. 2021 Nov 9. pii: 6424415. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2021
58. PATTYN J, Hendrickx G, Vorsters A, Van Damme P, et al
    Hepatitis B Vaccines.
    J Infect Dis. 2021;224.
    PubMed     Abstract available
    
    
    
59. AZMAN AS, Paul KK, Bhuiyan TR, Koyuncu A, et al
    Hepatitis E in Bangladesh: Insights from a National Serosurvey.
    J Infect Dis. 2021 Sep 22. pii: 6373659. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. WARD KM, Falade-Nwulia O, Moon J, Sutcliffe CG, et al
    Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs.
    J Infect Dis. 2021 Sep 20. pii: 6372878. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. RYDELL GE, Prakash K, Larsson SB, Skoglund C, et al
    Quantification of viral RNA in multiple pieces of explant liver tissue shows distinct focal differences of hepatitis B infection.
    J Infect Dis. 2021 Sep 17. pii: 6371942. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2021
62. CHANG KC, Chang MH, Chen HL, Wu JF, et al
    Universal Infant Hepatitis B Virus (HBV) Vaccination for 35 years: moving toward the Eradication of HBV.
    J Infect Dis. 2021 Aug 7. pii: 6345224. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2021
63. JOHNSON VALIENTE A, Liem KS, Schwarz KB, Rosenthal P, et al
    The Inflammatory Cytokine Profile Associated with Liver Damage is Broader and Stronger in Chronic Hepatitis B Patients Compared to Acute Hepatitis B Patients.
    J Infect Dis. 2021 Jul 21. pii: 6324833. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. SPRADLING PR, Xing J, Harris AM, Ly KN, et al
    Estimated prevalence and number of persons with isolated antibody to hepatitis B core antigen and associated occult hepatitis B, United States, 2001-2018.
    J Infect Dis. 2021 Jul 12. pii: 6319558. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. GU S, Wang W, Ye G, Chen C, et al
    Hepatocyte-derived L-carnitine restricts hepatitis B surface antigen loss through an immunosuppressive effect on germinal center-related immune cells.
    J Infect Dis. 2021 Jul 2. pii: 6313212. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2021
66. NDOW G, Cessay A, Cohen D, Shimakawa Y, et al
    Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa.
    J Infect Dis. 2021 Jun 23. pii: 6308183. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2021
67. HSU YC, Yeh ML, Wong GL, Chen CH, et al
    Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
    J Infect Dis. 2021 May 17. pii: 6276897. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2021
68. GONZALEZ HC, Trudeau S, Gordon SC
    Editorial: Changing trends in the US prevalence of hepatitis B core antibody provide important perspectives into future screening and vaccination strategies.
    J Infect Dis. 2021 Apr 27. pii: 6254533. doi: 10.1093.
    PubMed    
    
    
    
69. LY KN, Xing J, Spradling PR
    Trends in Prevalence and Characteristics of Resolved and Current Hepatitis B among US-Born Persons: National Health and Nutrition Examination Survey, 2001-2018.
    J Infect Dis. 2021 Apr 27. pii: 6254685. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. YUAN W, Huang D, Wu D, Chen Y, et al
    Peg IFN-a Treatment Enhanced the Inhibitory Effect of NK Cells on the Differentiation and Proliferation of CD4 +CD25 + Tregs via IFN-gamma in Chronic Hepatitis B.
    J Infect Dis. 2021 Apr 19. pii: 6236316. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. LIU Z, Huang CJ, Huang YH, Pan MH, et al
    HLA zygosity increases risk of hepatitis B virus-associated hepatocellular carcinoma.
    J Infect Dis. 2021 Apr 14. pii: 6225842. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2021
72. ARANDAY-CORTES E, McClure CP, Davis C, Irving WL, et al
    Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa.
    J Infect Dis. 2021 Mar 1. pii: 6154708. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2021
73. WU W, Wu D, Yan W, Wang Y, et al
    Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p.
    J Infect Dis. 2021;223:686-698.
    PubMed     Abstract available
    
    
    October 2020
74. YOSHIKAWA S, Yoshio S, Yoshida Y, Tsutsui Y, et al
    Impact of Immune Reconstitution-induced Hepatic Flare on HBsAg Loss in HBV/HIV-1-Coinfected Patients.
    J Infect Dis. 2020 Oct 19. pii: 5929874. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2020
75. WU JF, Chang KC, Ni YH, Hsu HY, et al
    Impacts of the percentage of basal core promoter mutation on the progression of liver fibrosis after HBeAg-seroconversion.
    J Infect Dis. 2020 Aug 29. pii: 5899201. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.